Patient Support 
for RYTELO

1. The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. REACH4RYTELO and its agents make no guarantee regarding coverage and reimbursement for RYTELO. Once you have been enrolled in REACH4RYTELO and a benefits investigation has been conducted, your doctor will receive a summary of the results of the benefits investigation. If information is missing, a Case Manager will follow up with your doctor. Your doctor should respond promptly to a request for further information from a Case Manager to avoid any delays.
2. The REACH4RYTELO Copay Program is not available to patients with any form of government insurance (such as Medicaid, Medicare, TRICARE, and VA). Patients must meet certain eligibility criteria to qualify for this program, including requirements related to the diagnosis for which the patient is receiving treatment and the patient’s insurance status. To enroll in the Copay Program, patients must first enroll in REACH4RYTELO. If eligible for the Copay Program, the patient may pay as little as $0 out-of-pocket for RYTELO with a maximum benefit of $9450 per year for the cost of the drug and a maximum benefit of $1200 per year for the cost of administration (up to $100 per infusion). An itemized EOB must be provided with a separate line for the out-of-pocket cost of administration fee. Residents of MA, MI, MN, and RI are not eligible to receive copay assistance for product administration and are therefore only eligible for a maximum benefit of $9450 per year for the cost of the drug. For Copay Program eligibility questions, contact a representative from REACH4RYTELO at 1-844-479-8356.

All programs provided through REACH4RYTELO are subject to eligibility requirements. Geron reserves the right to modify or discontinue REACH4RYTELO at any time without notice.